Synthetech Acquires Peptide Resin Technology From Colorado
News Jan 16, 2006
Synthetech, Inc. has acquired the technology assets and customer lists of Colorado Biotechnology Associates, Incorporated (CBA) for a range of cross-linked and functionalized polymeric resins used widely in Solid Phase Peptide Synthesis (SPPS).
Under the arrangement, Dr. Rodger Raubach, CBA's founder and principal owner, will transfer proprietary resin know-how to Synthetech, and serve as a consultant for scale-up, technical support, customer qualification and business development for a period of three years.
The transferred technology includes the procedure to attach the specified terminal amino acid to the resin, a key value-added service to peptide customers.
Synthetech plans to produce and have available for distribution resin batches within the next three months.
Commenting on the transaction, M. "Sreeni" Sreenivasan, Synthetech's President & CEO, said, "SPPS resins represent a product line that is complementary to our established line of peptide building blocks, with a distinct overlap in the customer base."
"Dr. Raubach has developed unique know- how and an enviable reputation in the field of SPPS resins over the past couple of decades. We look forward to working with Dr. Raubach and firmly establishing Synthetech as a world class supplier of high quality resins."
"We believe that with Dr. Raubach's assistance, Synthetech is well positioned to rapidly enter this market."
Dr. Raubach added, "With my desire to retire and wind up CBA, I believe there is no better choice to carry on the work I began in the resin field than Synthetech."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE